Logo do repositório
 
Publicação

Spectrum of Non-Nucleoside Reverse Transcriptase Inhibitor-Associated Drug Resistance Mutations in Persons Living with HIV-1 Receiving Rilpivirine

2024-11Artigo científico Acesso aberto
Ver registo simples
dc.contributor.authorEuResist Network
dc.contributor.authorZhou, Jinru
dc.contributor.authorAbecasis, Ana B.
dc.contributor.institutionLaboratório Associado de Translacção e Inovação para a Saúde Global - LA Real (Pólo IHMT)
dc.contributor.institutionTB, HIV and opportunistic diseases and pathogens (THOP)
dc.contributor.institutionGlobal Health and Tropical Medicine (GHTM)
dc.contributor.institutionInstituto de Higiene e Medicina Tropical (IHMT)
dc.contributor.pblMDPI - Multidisciplinary Digital Publishing Institute
dc.date.accessioned2025-03-13T21:14:55Z
dc.date.available2025-03-13T21:14:55Z
dc.date.issued2024-11
dc.descriptionFunding Information: This work was funded by a grant from the National Institutes of Health: 2R24AI13661806. The funder played no role in this review. Publisher Copyright: © 2024 by the authors.
dc.description.abstractIntroduction: Few data are currently available on the nonnucleoside reverse transcriptase (RT) inhibitors (NNRTI) resistance mutations selected in persons living with HIV-1 (PLWH) who develop virological failure while receiving rilpivirine (RPV). Methods: We analyzed pooled HIV-1 RT genotypic data from 280 PLWH in the multicenter EuResist database and 115 PLWH in the Stanford HIV Drug Resistance Database (HIVDB) who received RPV as their only NNRTI. Results: Among the 395 PLWH receiving RPV, 180 (45.6%) had one or more NNRTI-associated DRMs. Overall, 44 NNRTI-associated DRMs were identified, including 26 that occurred in two or more PLWHs. Seven mutations had a prevalence ≥10% among the 180 PLWH with one or more NNRTI-associated DRM: E138K (32.2%), V90I (25.0%), K101E (17.8%), Y181C (17.2%), E138A (13.9%), H221Y (12.2%), and K103N (10.6%). Y181C was significantly more likely to co-occur with K101E, V179F, H221Y, and M230L. Ten novel non-polymorphic mutations at known NNRTI-associated mutation positions were also identified, usually in just one PLWH: L100F, V108A, T139I, P225S, M230V, Y232C, and T240A/I/M/S. Conclusions: Our analysis extends the spectrum of mutations emerging in PLWH receiving RPV. Additional phenotypic characterization of RPV-selected mutations is necessary to better understand their biological and possible clinical significance.en
dc.description.versionpublishersversion
dc.description.versionpublished
dc.format.extent255955
dc.identifier.doi10.3390/v16111715
dc.identifier.issn1999-4915
dc.identifier.otherPURE: 112587087
dc.identifier.otherPURE UUID: 4b2a7ae7-0980-4a81-aef7-1e8fee09c6db
dc.identifier.otherScopus: 85210451085
dc.identifier.otherWOS: 001366566700001
dc.identifier.otherPubMed: 39599830
dc.identifier.otherPubMedCentral: PMC11599002
dc.identifier.urihttp://hdl.handle.net/10362/180594
dc.identifier.urlhttps://www.scopus.com/pages/publications/85210451085
dc.language.isoeng
dc.peerreviewedyes
dc.subjectHIV-1 drug resistance
dc.subjectnon-nucleoside reverse transcriptase inhibitors
dc.subjectrilpivirine
dc.subjectInfectious Diseases
dc.subjectVirology
dc.subjectSDG 3 - Good Health and Well-being
dc.titleSpectrum of Non-Nucleoside Reverse Transcriptase Inhibitor-Associated Drug Resistance Mutations in Persons Living with HIV-1 Receiving Rilpivirineen
dc.typejournal article
degois.publication.issue11
degois.publication.titleViruses
degois.publication.volume16
dspace.entity.typePublication
rcaap.rightsopenAccess

Ficheiros

Principais
A mostrar 1 - 1 de 1
Miniatura
Nome:
viruses-16-01715.pdf
Tamanho:
249.96 KB
Formato:
Adobe Portable Document Format
Ver/Abrir

Coleções

Home collection (IHMT)